Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version

The first version of the pharmacoeconomic (PE) guidelines was published in South Korea in 2006. Despite its first revision in 2011, there were still ambiguities in its interpretation. Moreover, methodologies for estimating effectiveness and costs have also evolved since then. Under these circumstanc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Applied health economics and health policy 2022-07, Vol.20 (4), p.467-477
Hauptverfasser: Bae, Eun-Young, Hong, Jihyung, Bae, SeungJin, Hahn, Seokyung, An, Hyonggin, Hwang, Eun-joo, Lee, Seung-min, Lee, Tae-jin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 477
container_issue 4
container_start_page 467
container_title Applied health economics and health policy
container_volume 20
creator Bae, Eun-Young
Hong, Jihyung
Bae, SeungJin
Hahn, Seokyung
An, Hyonggin
Hwang, Eun-joo
Lee, Seung-min
Lee, Tae-jin
description The first version of the pharmacoeconomic (PE) guidelines was published in South Korea in 2006. Despite its first revision in 2011, there were still ambiguities in its interpretation. Moreover, methodologies for estimating effectiveness and costs have also evolved since then. Under these circumstances, the Health Insurance Review and Assessment Service published the third version in January 2021. This article reviews the revision process and major changes made in the new edition of the PE guidelines. The revision was processed through reviews of the previous 50 PE submissions, international guidelines, academic literature, and surveys and advisory meetings to obtain stakeholders’ opinions. The analysis perspective has changed from a limited societal perspective to a healthcare system perspective. In addition to the drug with the highest market share, drugs used in clinical trials can be selected as comparators under certain conditions. The discount rate decreased from 5% to 4.5%. Furthermore, the revised guidelines provide more detailed and specific instructions for items including non-inferiority margin, extrapolation, utility elicitation, and uncertainty. Treatment switch and co-dependent technology guidelines are newly included; the budget impact analysis guideline is deleted. Through this revision, transparency and consistency of decision-making is expected to improve.
doi_str_mv 10.1007/s40258-022-00721-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2638716570</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638716570</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-1686a9d119896a7dfb39b482dc585ca53872e6d93e94c99f8a1507094093c9d3</originalsourceid><addsrcrecordid>eNp9kEtLxDAYRYMovv-ACym4cRPNu4k7GXQUBWcxug2ZJHUqbTMmreC_N059gAtXSfjOd3M5ABxhdIYRKs8TQ4RLiAiB-UkwZBtgF-NSQSyV2FzfOeSCkx2wl9ILQkQIxbbBDuWk5FTKXTC7C9GbrpgOtfNN3flUVCEWs6WJrbHB29CFtrbF1ZtpBtPXoUsXxePKmT6TdVf0S1_Ml3V0xZOPKY8PwFZlmuQPv859ML--mk9u4P3D9HZyeQ8tQ7KHWEhhlMNY5aqmdNWCqgWTxFkuuTW5XEm8cIp6xaxSlTSYoxIphhS1ytF9cDrGrmJ4HXzqdVsn65vGdD4MSRORE7DgJcroyR_0JQyxy-UyJRHljLJPioyUjSGl6Cu9inVr4rvGSH_q1qNunXXrtW7N8tLxV_SwaL37Wfn2mwE6AimPumcff__-J_YDxj2JHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2680354340</pqid></control><display><type>article</type><title>Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version</title><source>PAIS Index</source><source>SpringerLink Journals</source><creator>Bae, Eun-Young ; Hong, Jihyung ; Bae, SeungJin ; Hahn, Seokyung ; An, Hyonggin ; Hwang, Eun-joo ; Lee, Seung-min ; Lee, Tae-jin</creator><creatorcontrib>Bae, Eun-Young ; Hong, Jihyung ; Bae, SeungJin ; Hahn, Seokyung ; An, Hyonggin ; Hwang, Eun-joo ; Lee, Seung-min ; Lee, Tae-jin</creatorcontrib><description>The first version of the pharmacoeconomic (PE) guidelines was published in South Korea in 2006. Despite its first revision in 2011, there were still ambiguities in its interpretation. Moreover, methodologies for estimating effectiveness and costs have also evolved since then. Under these circumstances, the Health Insurance Review and Assessment Service published the third version in January 2021. This article reviews the revision process and major changes made in the new edition of the PE guidelines. The revision was processed through reviews of the previous 50 PE submissions, international guidelines, academic literature, and surveys and advisory meetings to obtain stakeholders’ opinions. The analysis perspective has changed from a limited societal perspective to a healthcare system perspective. In addition to the drug with the highest market share, drugs used in clinical trials can be selected as comparators under certain conditions. The discount rate decreased from 5% to 4.5%. Furthermore, the revised guidelines provide more detailed and specific instructions for items including non-inferiority margin, extrapolation, utility elicitation, and uncertainty. Treatment switch and co-dependent technology guidelines are newly included; the budget impact analysis guideline is deleted. Through this revision, transparency and consistency of decision-making is expected to improve.</description><identifier>ISSN: 1175-5652</identifier><identifier>EISSN: 1179-1896</identifier><identifier>DOI: 10.1007/s40258-022-00721-4</identifier><identifier>PMID: 35275388</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Clinical trials ; Committees ; Compliance ; Costs ; Decision making ; Discount rates ; Health Administration ; Health care industry ; Health Economics ; Health insurance ; Impact analysis ; Leading Article ; Market shares ; Medicine ; Medicine &amp; Public Health ; Meetings ; Pharmaceutical industry ; Pharmacoeconomics ; Pharmacoeconomics and Health Outcomes ; Public Health ; Quality of Life Research ; Revisions</subject><ispartof>Applied health economics and health policy, 2022-07, Vol.20 (4), p.467-477</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>Copyright Springer Nature B.V. Jul 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-1686a9d119896a7dfb39b482dc585ca53872e6d93e94c99f8a1507094093c9d3</citedby><cites>FETCH-LOGICAL-c408t-1686a9d119896a7dfb39b482dc585ca53872e6d93e94c99f8a1507094093c9d3</cites><orcidid>0000-0003-2539-3579</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40258-022-00721-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40258-022-00721-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27866,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35275388$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bae, Eun-Young</creatorcontrib><creatorcontrib>Hong, Jihyung</creatorcontrib><creatorcontrib>Bae, SeungJin</creatorcontrib><creatorcontrib>Hahn, Seokyung</creatorcontrib><creatorcontrib>An, Hyonggin</creatorcontrib><creatorcontrib>Hwang, Eun-joo</creatorcontrib><creatorcontrib>Lee, Seung-min</creatorcontrib><creatorcontrib>Lee, Tae-jin</creatorcontrib><title>Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version</title><title>Applied health economics and health policy</title><addtitle>Appl Health Econ Health Policy</addtitle><addtitle>Appl Health Econ Health Policy</addtitle><description>The first version of the pharmacoeconomic (PE) guidelines was published in South Korea in 2006. Despite its first revision in 2011, there were still ambiguities in its interpretation. Moreover, methodologies for estimating effectiveness and costs have also evolved since then. Under these circumstances, the Health Insurance Review and Assessment Service published the third version in January 2021. This article reviews the revision process and major changes made in the new edition of the PE guidelines. The revision was processed through reviews of the previous 50 PE submissions, international guidelines, academic literature, and surveys and advisory meetings to obtain stakeholders’ opinions. The analysis perspective has changed from a limited societal perspective to a healthcare system perspective. In addition to the drug with the highest market share, drugs used in clinical trials can be selected as comparators under certain conditions. The discount rate decreased from 5% to 4.5%. Furthermore, the revised guidelines provide more detailed and specific instructions for items including non-inferiority margin, extrapolation, utility elicitation, and uncertainty. Treatment switch and co-dependent technology guidelines are newly included; the budget impact analysis guideline is deleted. Through this revision, transparency and consistency of decision-making is expected to improve.</description><subject>Clinical trials</subject><subject>Committees</subject><subject>Compliance</subject><subject>Costs</subject><subject>Decision making</subject><subject>Discount rates</subject><subject>Health Administration</subject><subject>Health care industry</subject><subject>Health Economics</subject><subject>Health insurance</subject><subject>Impact analysis</subject><subject>Leading Article</subject><subject>Market shares</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Meetings</subject><subject>Pharmaceutical industry</subject><subject>Pharmacoeconomics</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Public Health</subject><subject>Quality of Life Research</subject><subject>Revisions</subject><issn>1175-5652</issn><issn>1179-1896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>7TQ</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kEtLxDAYRYMovv-ACym4cRPNu4k7GXQUBWcxug2ZJHUqbTMmreC_N059gAtXSfjOd3M5ABxhdIYRKs8TQ4RLiAiB-UkwZBtgF-NSQSyV2FzfOeSCkx2wl9ILQkQIxbbBDuWk5FTKXTC7C9GbrpgOtfNN3flUVCEWs6WJrbHB29CFtrbF1ZtpBtPXoUsXxePKmT6TdVf0S1_Ml3V0xZOPKY8PwFZlmuQPv859ML--mk9u4P3D9HZyeQ8tQ7KHWEhhlMNY5aqmdNWCqgWTxFkuuTW5XEm8cIp6xaxSlTSYoxIphhS1ytF9cDrGrmJ4HXzqdVsn65vGdD4MSRORE7DgJcroyR_0JQyxy-UyJRHljLJPioyUjSGl6Cu9inVr4rvGSH_q1qNunXXrtW7N8tLxV_SwaL37Wfn2mwE6AimPumcff__-J_YDxj2JHA</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Bae, Eun-Young</creator><creator>Hong, Jihyung</creator><creator>Bae, SeungJin</creator><creator>Hahn, Seokyung</creator><creator>An, Hyonggin</creator><creator>Hwang, Eun-joo</creator><creator>Lee, Seung-min</creator><creator>Lee, Tae-jin</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>4T-</scope><scope>7TQ</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DHY</scope><scope>DON</scope><scope>DPSOV</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KC-</scope><scope>L.-</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2L</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2539-3579</orcidid></search><sort><creationdate>20220701</creationdate><title>Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version</title><author>Bae, Eun-Young ; Hong, Jihyung ; Bae, SeungJin ; Hahn, Seokyung ; An, Hyonggin ; Hwang, Eun-joo ; Lee, Seung-min ; Lee, Tae-jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-1686a9d119896a7dfb39b482dc585ca53872e6d93e94c99f8a1507094093c9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical trials</topic><topic>Committees</topic><topic>Compliance</topic><topic>Costs</topic><topic>Decision making</topic><topic>Discount rates</topic><topic>Health Administration</topic><topic>Health care industry</topic><topic>Health Economics</topic><topic>Health insurance</topic><topic>Impact analysis</topic><topic>Leading Article</topic><topic>Market shares</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Meetings</topic><topic>Pharmaceutical industry</topic><topic>Pharmacoeconomics</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Public Health</topic><topic>Quality of Life Research</topic><topic>Revisions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bae, Eun-Young</creatorcontrib><creatorcontrib>Hong, Jihyung</creatorcontrib><creatorcontrib>Bae, SeungJin</creatorcontrib><creatorcontrib>Hahn, Seokyung</creatorcontrib><creatorcontrib>An, Hyonggin</creatorcontrib><creatorcontrib>Hwang, Eun-joo</creatorcontrib><creatorcontrib>Lee, Seung-min</creatorcontrib><creatorcontrib>Lee, Tae-jin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>PAIS Index</collection><collection>Access via ABI/INFORM (ProQuest)</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>Politics Collection</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Politics Collection</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Political Science Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Applied health economics and health policy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bae, Eun-Young</au><au>Hong, Jihyung</au><au>Bae, SeungJin</au><au>Hahn, Seokyung</au><au>An, Hyonggin</au><au>Hwang, Eun-joo</au><au>Lee, Seung-min</au><au>Lee, Tae-jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version</atitle><jtitle>Applied health economics and health policy</jtitle><stitle>Appl Health Econ Health Policy</stitle><addtitle>Appl Health Econ Health Policy</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>20</volume><issue>4</issue><spage>467</spage><epage>477</epage><pages>467-477</pages><issn>1175-5652</issn><eissn>1179-1896</eissn><abstract>The first version of the pharmacoeconomic (PE) guidelines was published in South Korea in 2006. Despite its first revision in 2011, there were still ambiguities in its interpretation. Moreover, methodologies for estimating effectiveness and costs have also evolved since then. Under these circumstances, the Health Insurance Review and Assessment Service published the third version in January 2021. This article reviews the revision process and major changes made in the new edition of the PE guidelines. The revision was processed through reviews of the previous 50 PE submissions, international guidelines, academic literature, and surveys and advisory meetings to obtain stakeholders’ opinions. The analysis perspective has changed from a limited societal perspective to a healthcare system perspective. In addition to the drug with the highest market share, drugs used in clinical trials can be selected as comparators under certain conditions. The discount rate decreased from 5% to 4.5%. Furthermore, the revised guidelines provide more detailed and specific instructions for items including non-inferiority margin, extrapolation, utility elicitation, and uncertainty. Treatment switch and co-dependent technology guidelines are newly included; the budget impact analysis guideline is deleted. Through this revision, transparency and consistency of decision-making is expected to improve.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>35275388</pmid><doi>10.1007/s40258-022-00721-4</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2539-3579</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1175-5652
ispartof Applied health economics and health policy, 2022-07, Vol.20 (4), p.467-477
issn 1175-5652
1179-1896
language eng
recordid cdi_proquest_miscellaneous_2638716570
source PAIS Index; SpringerLink Journals
subjects Clinical trials
Committees
Compliance
Costs
Decision making
Discount rates
Health Administration
Health care industry
Health Economics
Health insurance
Impact analysis
Leading Article
Market shares
Medicine
Medicine & Public Health
Meetings
Pharmaceutical industry
Pharmacoeconomics
Pharmacoeconomics and Health Outcomes
Public Health
Quality of Life Research
Revisions
title Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A30%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Korean%20Guidelines%20for%20Pharmacoeconomic%20Evaluations:%20Updates%20in%20the%20Third%20Version&rft.jtitle=Applied%20health%20economics%20and%20health%20policy&rft.au=Bae,%20Eun-Young&rft.date=2022-07-01&rft.volume=20&rft.issue=4&rft.spage=467&rft.epage=477&rft.pages=467-477&rft.issn=1175-5652&rft.eissn=1179-1896&rft_id=info:doi/10.1007/s40258-022-00721-4&rft_dat=%3Cproquest_cross%3E2638716570%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2680354340&rft_id=info:pmid/35275388&rfr_iscdi=true